 |
|
|
| |
No Resistance to Tenofovir Disoproxil Fumarate (TDF) Detected Following up to 192 Weeks of Treatment in Subjects Mono-Infected with Chronic Hepatitis B Virus
|
| |
| |
Reported by Jules Levin
AASLD Nov 1 2010 Boston
AASLD: Long Term (4 Year) Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) with Chronic Hepatitis B (Study 103) - (11/04/10)
AASLD: Continued Efficacy and Safety Through 4 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/04/10)
A Snow-Lampart1, K Kitrinos1, B Chappell1, F Myrick1, J Schawalder1, E J Heathcote2, P Marcellin3, and K Borroto-Esoda1
1Gilead Sciences, NC, USA; 2Toronto General Hospital, Ontario, Canada; 3Hospital Beaujon, Clichy, France
|
| |
|
|
|
|
|
